Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dihydroartemisinin + piperaquine + azithromycin
- Development stage
- Unknown
- Lead developer
- Liverpool School of Tropical Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dihydroartemisinin-piperaquine + azithromycin is an investigational combination regimen evaluated for intermittent preventive treatment in pregnancy (IPTp). It combines dihydroartemisinin-piperaquine (DP), an artemisinin-based combination therapy (ACT), with azithromycin, a broad-spectrum macrolide antibiotic. The regimen is designed to prevent malaria and sexually transmitted or reproductive tract infections (STIs/RTIs) in pregnant women, particularly in regions with high resistance to the standard treatment, sulfadoxine-pyrimethamine. The combination was studied in the Phase 3 IMPROVE trial led by the Liverpool School of Tropical Medicine, which compared monthly IPTp-DP alone or with a single course of azithromycin against the standard of care in East Africa.
- Other names
- dihydroartemisinin-piperaquine plus azithromycinDP + AZ
02
Targets
Plasmodium falciparum apicoplast 50S ribosomal subunitHemePfHRP2 (Plasmodium falciparum histidine-rich protein II)Bacterial 50S ribosomal subunitATP2A (Sarcoplasmic reticulum Ca2+-ATPase)
Beyond the preview
Go deeper on dihydroartemisinin + piperaquine + azithromycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dihydroartemisinin + piperaquine + azithromycin.